NCT05344404View on ClinicalTrials.gov

NR-SAFE: Safety of High-dose Nicotinamide Riboside (NR) in Parkinson's Disease

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 29, 2022

Primary Completion Date

July 1, 2022

Study Completion Date

July 1, 2022

Conditions
Parkinson Disease
Interventions
DIETARY_SUPPLEMENT

Nicotinamide Riboside

3000mg total daily. Administered in capsule form in doses of 1500mg twice daily for the duration of the trial (4 weeks).

DIETARY_SUPPLEMENT

Placebo

Placebo drug. Administered in tablet form twice daily for the duration of the trial (4 weeks).

Trial Locations (1)

Unknown

Haukeland University Hospital, Bergen

All Listed Sponsors
lead

Haukeland University Hospital

OTHER